Akers Biosciences (AKER) Prices 1.99M Unit Offering at $4/Unit
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Akers Biosciences (AKER) will continue strategic review and has identified hemp and minor cannabinoid sectors as promising adjacent opportunities
December 5, 2019 8:47 AM ESTAkers Biosciences, Inc. (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it will continue its strategic review and has identified the hemp and minor cannabinoid sectors as promising adjacent opportunities that could benefit from Akers core competencies. The company is exploring how to leverage its 30 years of operational history in its medical device business, where its current products have U.S. Food and Drug Administration (FDA) clearance, its current operations practice Good Manufacturing Processes (cGMP), its medical device facility is certified under ISO 13485 2016 and the facility carries an Analytical Lab Certification for Schedules... More
